Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Comment by Abitoon Oct 02, 2020 11:43pm
242 Views
Post# 31662413

RE:RE:RE:RE:RE:RE:RE:Great 👍, , Waves cancer drug approved in Europe

RE:RE:RE:RE:RE:RE:RE:Great 👍, , Waves cancer drug approved in Europe i agree... and the way its trading in such a tight reange thier might be a financing in the works.



MirrorWorldMan wrote: No doubt about it,these guys need cash soon.  Likely within the next quarter.  Even with potential help from any comercial partners their cash burn is at least .5 MM a quarter.  As low and respected as that is, their cash and receiveables are not enough to get them to the new year by my calculations and its a miracle they got through this far. I have seen this before in a high potential  BT's and its indicativie of something in the works.  Look for some kind of announcement soon dealing with financing or partners (or both).  Keep fingers crossed its not a a general offering but rather a strategic placement of shares in exchange for financing with a partner somewhere.  Hold tight, help is on the way (there is no choice).


<< Previous
Bullboard Posts
Next >>